AstraZeneca Should Stick to Its Winning Formula AstraZeneca's market value stands at around $200 billion, while Bristol Myers Squibb's is approximately $150 billion.
Combining these two companies would create a pharmaceutical behemoth with an unmatched presence in oncology, but at what cost?
The merger would come with a significant price tag, including the assumption of debt and substantial cost cutting measures.